GlassScriptPhysician profile
Kevin Michael Wymer
NPI 1770947434
$16,015.95
in general payments reported to CMS, 2019-2025
7 companies · $9,052 in 2025
The $9,052 reported for 2025 was more than what 93% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $73.22 · 2021: $4,805 · 2022: $101 · 2023: $617 · 2024: $1,118 · 2025: $9,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,950 · Travel and Lodging: $2,730 · Food and Beverage: $2,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,950.00 |
| Travel and Lodging | $2,729.63 |
| Food and Beverage | $2,107.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $8,845.17 | 2019-2025 | General - Kidney Stone Disease, General - Therapies, Lumenis Pulse 120h |
| Ethicon INC. | $4,805.38 | 2021 | |
| Calyxo, INC. | $2,149.63 | 2022-2025 | Cvac Aspiration System |
| Karl Storz Endoscopy-America | $79.82 | 2023-2024 | Scopesafelaser Fiber |
| Procept Biorobotics Corporation | $59.01 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.89 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.05 | 2023 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Wymer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.